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Angiotensin in colorectal cancer 
Abstract : Colorectal cancer (CRC) cels poss巴ssan angiotensin activation mechanism provided 
by the expression of renin and chymase. Renin expression is induced by hyp巴rglycemic
condition. Since angiotensinogen is produced in the liver， CRC cels with angiotensin-activating 
machinery possess an advantage to metastasize to the liver. In human CRC cases， the diabetes 
complicated patients show higher concentrations of renin， angiotensin同Iin the primary tumors， 
and more progressed disease stage， especially， liver metastasis in an association with HbAlc 
levels than those in the patients without diabetes. Concurrent treatment with anti-angiotensin 
and hypoglycemic agents shows a synergic effect of decrease of liver metastasis and 
improvement of the survival of diabetic mice of CRC liver metastasis model. The effect of anti-
angiotensin treatment and blood sugar control as a baseline management of the colon cancer 
patients with the diabetic condition is needed to be examined in c1inical situation for prev巴ntion
of liver metastasis. 
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Angiotensin prornotes cancer progression 
Colorectal cancer (CRC) is the third leading cause of cancer death in J apan， and the cancer 
mortality is stil increasing a s the Western lifestyle gains popularity among the J apanese 
population 1). Approximately 24% of CRC cases involving invasion beyond the submucosallayer 
showed liver metastasis during and/or after the operation 2). One-third of CRC patients died 
of liver metastasis 3). Only one-third or fewer CRC patients with liver metastasis respond to 
systemic chemotherapy， however， and long-term survival is rare 3). The 5-year survival rate 
of CRC patients with liver m巴tastasisis less than 20% 1). Early detection and control of liver 
metastasis is therefore an important issue for the treatment of CRCs. 
Angiotensin-II (A-I) has multiple physiologic efects; activation of A-II type 1 receptor (ATRl) 
by A-II eventually leads to vasoconstriction， in:fiammation， and proliferation in cardiovascular 
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and neoplastic tissues 41A TR1 intracellular signaling pathways produce diverse efects: A TR1 
induces activation of protein kinase C， angiopoietin 2， vascular endothelial growth factor (VEGF)， 
VEGF r巴ceptors，fibroblast growth factor， platelet-derived growth factor， transforming growth 
factor beta， epidermal growth factor， nitric oxide synthase， and metalloproteinase 4，51. Th巴se
properties enhance colon carcinogenesis and disease progression. 
We have confirmed the protumoral effect of angiotensin by experiment. Effects of A-II on cel 
growth， invasion， and apoptosis are examined in the CRC celllin巴S61. A-I enhances cel growth 
and in vitro invasion into type 1V collagen in a dose-dependent manner. 1n contrast， apoptosis 
is decreased by A-II in a dose-dependent manner. Reduction of hepatic angiotensinogen (ATG) 
production by knockdown with cholesterol-conjugated antisense S田oligodeoxynucleotide(S-ODN) 
suppressed liver metastasis of HT29 cels in nude mice liver metastasis model. A TG同knockdown
mice show less pronounced size， number， Ki-67 labeling index， and microvessel density in the 
metastatic foci than those in the control mice. Knockdown of renin or chymase in HT29 cels 
show smaller and less numbered metastatic foci in the liver than those in control. Furthermore 
the examination of 121 CRC patients shows that the serum A-II concentration is significantly 
associated with advanced disease stage， esp巴cially，the liver metastasis. 
Angiotensin activation in CRC cells 
A TG is an inactive precursor of A田I(Fig. 1). A TG poss巴ssesno effect on cancer cels without 
conversion to A-1I. Effects of ATG on cel growth， invasion， and apoptosis are examined in HT29 
cels. 1nterestingly， A TG enhanced cel growth， in vitro invasion， and anti-apoptotic survival in 
HT29 cels in a dos巴-dependentmanner as shown as treatment with A同1I.This finding suggests 
that the HT29 cels have angiotensin-activating machinery by themselves. 
We then examine the expression of angiotensin-associated genes in HT29 cels. They express 
ATRl， but do not express ATG or angiotensin 1 (A-1) converting enzyme (ACE). However， they 
express chymase， which possesses an ACE-like activity. Renin is also expressed in HT29 cels. 
Moreover， a renin inhibitor abrogates the production of both A-1 and A-1I. A chymase inhibitor 
suppresses the production of A-II but not that of A-I. 1n contrast， an ACE inhibitor does not 
affect the production of A-1 or A-II in HT29 cels. Thus， A同Iis produced from A TG by r巴nm
and chymase in HT29 cels. Chymase， tonin， and cathepsin G al possess an ACE】likeactivity， 
which can be used as a substitute for ACE (Fig. 1) 71. Cathepsin D is responsible for producing 
A-1 from ATG in cardiac myocytes， fibroblasts， and vascular smooth muscle cels in place of 
renin 81. However， the CRC cels in this study do not express cathepsin D. Chymase expression 
is associated with hypoxia or ischemia in the human left cardiac ventricle 91; however， itis not 
associated with hyperglycemia in CRC cels 61. 
MASl 
MAS1 is a receptor of an angiotensin I (A-I) degenerative product by angiotensin 
converting enzyme 2， angiotensin 1-7 (Al-7)， which provide anti-A-II phenotypes， such as 
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vessel dilation， depression of blood pressure (Fig. 1) 10). We examin巴 arole of MAS1 in CRC 
and invasive ductal carcinoma (IDC) of th巴 breast11). By immunohistochemistry， MAS1 is not 
detected in CRCs and the normal colon mucosa. The normal mammary lobules and ducts 
express MAS1 at high levels， whereas MAS1 expression is attenuated in al1 IDCs. Especial1y， 
MAS1 expression is highly decreased in scirrhous type IDCs than that in other types. The 
decrease of MAS1 expression is associated with lymph node metastasis but not T factor， grade， 
status of estrogen receptor or progesterone receptor. The decrease of MAS1 expression is 
reversely associated with HER2 expression. Using a mouse breast cancer c巴1line， BALB-MC， 
which expressed MASl， cel1 growth and in vitro invasion are examined. Al-7 treatment inhibits 
growth and invasion of BALB-MC cel1s， which are abrogated by MAS1 knockdown. MAS1 
intracel1ular signaling involves Akt phosphorylation， protein kinase C activation and mitogen-
activat巴dprotein (MAP) kinase inhibition 12). These findings suggest that MAS1 might act as an 
inhibitory regulator of breast tissues and the cancer. 
CDI0 
CD10， known as common acute lymphoblastic leukemia antigen (CALLA)， isa characteristic 
mark巴rof various subgroups of B-cel1 type-acute lymphocytic leukemias 13.14). It is a zinc同
dependent membrane metal1oendopeptidase， also cal1ed as neutral endopeptidase (EC 3.4.24.1)， 
enkephalinase， or neprilysin 14) CD10 is expressed in CRC and is associated with CRC 
metastases， especial1y liver metastasis. 2.15.1町.Met-enkephalin (MENK) is a high a:finity substrate 
of CD10 17，1剖.MENK is produced by hepatocytes under the ce11ular stress condition， such as 
hepatitis， bile stasis， and liver metastasis 19剖.MENK inhibits tumor growth and establish of 
metastatic foci 22). CDlO回positiveCRC c巴1sdegrade MENK and escape from MENK-induced 
tumor suppression 2). CD10 possesses a weak affinity to A-I 23); how巴ver，CD10 shows A凶I
degrading activity but not the A-I convertizing activity. Degrading of A-I produces Al-7， a 
MAS1 ligand. As mention巴dabove， MAS1 is not expressed in CRCs. CD10-induced Al-7 does 
not affect CRC progression 
Diabetes and renin/ angiotensin system 
Diabetes mel1itus is a common problem in countries adopting the Western lifestyle. The results 
of several epidemiological studies show an association between type 2 diabetes and the risk of 
colorectal， pancreatic， breast， liver， gastric， and endometrial cancer 24). The risk of malignancies 
is increased at earlier stages in cases of abnormalities in glucose me tabolism， and there is a 
linear relationship between cancer risk and plasma insulin levels 24). With regard to CRCs， a 
metaanalysis of 15 studies， including 2，593，935 participants， showed that diabetes is associated 
with an increased risk of CRC (relative risk， 1.30; 95% CI， 1.20 :t 1.40). Diabetes isalso associated 
with CRC mortality (relative risk， 1.26; 95% CI， 1.05土1.50)25). High glycated hemoglobin (HbA1c) 
levels are also associated with an incr巴asedrisk of CRC (odds ratio， 1.57; 95% CI， 0.94 :t 2.60) 26). 
In several studies， ithas been demonstrated that hyperinsulinemia， elevated levels of C-peptide， 
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elevated body mass index， high levels of insulin growth factorよ lowlevels of insulin growth 
factor binding protein-3， high leptin levels， and low adiponectin levels are al involved in 
carcinogenesis 27). Increased blood concentrations of insulin and insulin-like growth factor are 
particularly important in enhancing the risk of CRC 28). However， a detailed understanding of 
how diabetes might increase the risk of CRC is stilllacking. 
We examined the expression of renin in HT29 and CT26 cels in association with changing 
glucose concentration. When the medium contained 100 mg/dl glucose， renin protein was 
detected in only HT29 cels but not in CT26 cels. When the medium contained glucose at 200 
mg/dl or more， the expression of renin increased with increasing glucose concentration in a 
dose-dependent manner in the two cel lines. CT26 cels also express chymase but not ACE in 
similar to HT29 cels. Then these CRC cels activate angiotensin in a high glucos巴condition.
In the hyperglycemic mice fed with high glucose diet， the size， number， Ki-67 labeling 
index， and microvessel density were pronounced in the liver metastatic foci than those in the 
normoglycemic mice fed with the control diet. In the clinical situations， this scheme is confirmed. 
In the examination of 121 CRC patients， the tumoral renin concentration correlated with 
HbA1c levels and the tumoral A-II concentration correlated with tumoral renin concentration. 
Moreover， the high blood HbA1c is associated with the higher incidence of liver metastasis in 
diabetic cases than in nondiabetic cases. In cardiac fibroblasts， a high concentration of glucose 
significantly increases intracellular A目立 levels by increasing the intracellular levels of renin 29) 
A-II and liver metastasis 
A-II precursor， AGT is mainly produced in the hepatocytes 30). We confirm that CRC cels 
possessing angiotensin-activating ability establish liver metastasis because these cells can 
produce abundant A-II from AGT in the liver 6). We suppress AGT production in the mouse 
liver by using pro-AGT antisense S-ODN， which significantly suppresses the liver metastasis 
of CRC cels. Thus CRC cels with angiotensin-activating ability possess advantages for liv巴r
metastasis. In CRC cases， A-I is associated with renin concentration in the primary tumors 6). Thus 
the pres巴nceof a large amount of A-II in primary CRC tissues， which suggests the potential 
angiotensin-activating ability of CRC cells， was associated with a high frequency of liver 
metastasis. Hence， A-II concentration in primary CRC tissues is suggested as a good marker for 
liver metastasis. 
Angiotensin targeting therapy 
The renin/angiotensin-activating system is recognized as an important molecular target for 
CRC prevention and treatment. Several inhibitors of the renin/angiotensin-activating system 
suppress cancer development， cancer cel growth， angiogenesis， and metastasis 4，5，31，34). Inhibitors 
of the renin-angiotensin system are widely used to treat hypertension. We have observed some 
antiangiotensin agents， inhibitors of renin and chymase， suppressed liver metastasis of CRCs 
，35). ACE inhibitors and/or A-I receptor blocker (ARB) have been reported to improve disease 
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prognosis or progression in pancreatic and urogenital cancer 36.3η 
Further， we examine the combined effect of anti-angiotensin treatment and hypoglycemic 
treatment 351. In a streptozotocin-induced BALB/c mouse diabetes model that is fed a high-
calorie diet， the blood sugar level increases and is associated with increasing siz巴 and
number of CT26 cel liver metastases. In this diabetic mouse model， e狂ectof the concurrent 
hypoglyc巴micand anti-angiotensin treatments is examined 351. Insulin and glic1azide (sulfonylurea) 
are administered with or without a renin inhibitor， aliskiren in the liver metastasis model using 
mice fed with high calory diet and treated with streptozotocin injection. Treatment with insulin 
and glic1azide results in lower blood sugar levels compared to that in the untreated mice. The 
mice treated with insulin or glic1azide show a decrease in the number of metastatic foci and 
improved survival than those in the untreated mice. Concurrent treatm巴ntwith anti引 19lOtensm
using aliskiren or captopril (ARB) and hypoglycemic agents (insulin or glic1azide) results in 
lower serum A-II concentration， smaller number of metastatic foci， and longer survival than 
those in the untreated mice or the mice treated with hypoglycemic agents alone. Combined 
treatment with anti-angiotensin and hypoglycemic agents showed a synergistic inhibitory effect 
on liver metastasis. The mice treated with the combination show suppression of liver metastasis 
and improved survival， which is indistinguishable from that of the control mice. 
Given that the association between hyperglycemia and liver metastasis in colon cancer is 
a result of renin upregulation， diabetes status is likely to b巴 arisk factor for liver metastasis. 
Control of blood sugar could， therefore， be important in preventing liver metastasis in colon 
cancer patients. The use of anti-angiotensin treatment and blood sugar control as a baseline 
management for colon cancer patients with diabetes deserves to be examined in c1inical trials 
in order to establish whether it helps in the prevention of liver metastasis (Fig. 1). 
Angiotensin metabolism， 




Figure 1. Processing and signaling pathways of angiotensin and potential points at which they can be inhibited 
The signaling and processing pathways of angiotensin are displayed with the enzymes responsible for each process and 
their inhibitor. Angiotensin I， angiotensin II. and angiotensin 1-7 al have physiological activities 
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